Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2 Checkpoint and Inhibition of Homologous Recombinational DNA Repair

Ries, 2008, SEER Cancer Statistics Review, 1975-2005

Loehrer, 2008, A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201, J Clin Oncol, 26, 10.1200/jco.2008.26.15_suppl.4506

McGinn, 2001, Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer, J Clin Oncol, 19, 4202, 10.1200/JCO.2001.19.22.4202

Morgan, 2008, Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells, Transl Oncol, 1, 36, 10.1593/tlo.07106

Morgan, 2008, The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer, Clin Cancer Res, 14, 5142, 10.1158/1078-0432.CCR-07-4072

Liu, 2000, Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint, Genes Dev, 14, 1448, 10.1101/gad.14.12.1448

Zhao, 2002, Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints, Proc Natl Acad Sci U S A, 99, 14795, 10.1073/pnas.182557299

Sorensen, 2005, The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair, Nat Cell Biol, 7, 195, 10.1038/ncb1212

Karnitz, 2005, Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival, Mol Pharmacol, 68, 1636, 10.1124/mol.105.012716

Carrassa, 2004, Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53, Cell Cycle, 3, 1177, 10.4161/cc.3.9.1080

Hu, 2001, The radioresistance to killing of A1–5 cells derives from activation of the Chk1 pathway, J Biol Chem, 276, 17693, 10.1074/jbc.M009340200

Janetka, 2007, Inhibitors of checkpoint kinases: from discovery to the clinic, Curr Opin Drug Discov Dev, 10, 473

Zabludoff, 2008, AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies, Mol Cancer Ther, 7, 2955, 10.1158/1535-7163.MCT-08-0492

Tao, 2009, Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints, Cell Cycle, 8, 1196, 10.4161/cc.8.8.8203

Matthews, 2007, Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo, Cell Cycle, 6, 104, 10.4161/cc.6.1.3699

Blasina, 2008, Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1, Mol Cancer Ther, 7, 2394, 10.1158/1535-7163.MCT-07-2391

Wang, 1996, UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53, J Natl Cancer Inst, 88, 956, 10.1093/jnci/88.14.956

Kortmansky, 2005, Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors, J Clin Oncol, 23, 1875, 10.1200/JCO.2005.03.116

Fuse, 2005, Review of UCN-01 development: a lesson in the importance of clinical pharmacology, J Clin Pharmacol, 45, 394, 10.1177/0091270005274549

Parry, 2009, Targeting the replication checkpoint with a potent and selective CHK1 inhibitor, Abstract number 2490

Ashwell, 2008, DNA damage detection and repair pathways—recent advances with inhibitors of checkpoint kinases in cancer therapy, Clin Cancer Res, 14, 4032, 10.1158/1078-0432.CCR-07-5138

Bucher, 2008, G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer, Br J Cancer, 98, 523, 10.1038/sj.bjc.6604208

Morgan, 2005, Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine, Cancer Res, 65, 6835, 10.1158/0008-5472.CAN-04-2246

Arlander, 2003, Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress, J Biol Chem, 278, 52572, 10.1074/jbc.M309054200

Morgan, 2006, The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment, Cell Cycle, 5, 1983, 10.4161/cc.5.17.3184

Parsels, 2009, Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells, Mol Cancer Ther, 8, 45, 10.1158/1535-7163.MCT-08-0662

Lawrence, 1988, Ouabain sensitizes tumor cells but not normal cells to radiation, Int J Radiat Oncol Biol Phys, 15, 953, 10.1016/0360-3016(88)90132-0

Fertil, 1984, Mean inactivation dose: a useful concept for intercomparison of human cell survival curves, Radiat Res, 99, 73, 10.2307/3576448

Huang, 2004, Detection of histone H2AX phosphorylation on Ser-139 as an indicator of DNA damage (DNA double-strand breaks), Curr Protoc Cytom, Chapter 7, Unit 7.27

Hoy, 1989, Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): critical factors that affect the amount of fluorescence and the shape of BrdUrd/DNA histogram, Cytometry, 10, 718, 10.1002/cyto.990100608

Pierce, 1999, XRCC3 promotes homology-directed repair of DNA damage in mammalian cells, Genes Dev, 13, 2633, 10.1101/gad.13.20.2633

Li, 2007, Identification of pancreatic cancer stem cells, Cancer Res, 67, 1030, 10.1158/0008-5472.CAN-06-2030

Lindstrom, 1993, Global comparison of radiation and chemotherapy dose-response curves with a test for interaction, Radiat Res, 135, 269, 10.2307/3578305

Mailand, 2000, Rapid destruction of human Cdc25A in response to DNA damage, Science, 288, 1425, 10.1126/science.288.5470.1425

Zhang, 2005, Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway, Mol Cell, 19, 607, 10.1016/j.molcel.2005.07.019

Syljuasen, 2004, Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation, Cancer Res, 64, 9035, 10.1158/0008-5472.CAN-04-2434

Ganzinelli, 2008, Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil, Clin Cancer Res, 14, 5131, 10.1158/1078-0432.CCR-08-0304

Han, 2002, Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray, Cancer Res, 62, 2890

Vispe, 1998, Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation, Nucleic Acids Res, 26, 2859, 10.1093/nar/26.12.2859

Maitra, 2006, Molecular pathogenesis of pancreatic cancer, Best Pract Res Clin Gastroenterol, 20, 211, 10.1016/j.bpg.2005.10.002

Maacke, 2000, DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma, Oncogene, 19, 2791, 10.1038/sj.onc.1203578

Frankenberg-Schwager, 2009, Single-strand annealing, conservative homologous recombination, nonhomologous DNA end joining, and the cell cycle-dependent repair of DNA double-strand breaks induced by sparsely or densely ionizing radiation, Radiat Res, 171, 265, 10.1667/RR0784.1

Mladenov, 2009, The complexity of double-strand break ends is a factor in the repair pathway choice, Radiat Res, 171, 397, 10.1667/RR1487.1

Wang, 2003, Caffeine could not efficiently sensitize homologous recombination repair-deficient cells to ionizing radiation-induced killing, Radiat Res, 159, 420, 10.1667/0033-7587(2003)159[0420:CCNESH]2.0.CO;2

Wachters, 2003, Selective targeting of homologous DNA recombination repair by gemcitabine, Int J Radiat Oncol Biol Phys, 57, 553, 10.1016/S0360-3016(03)00503-0

Lawrence, 1996, Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine, Int J Radiat Oncol Biol Phys, 34, 867, 10.1016/0360-3016(95)02134-5

Ahn, 2000, Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation, Cancer Res, 60, 5934

Morgan, 2008, Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review, Clin Cancer Res, 14, 6744, 10.1158/1078-0432.CCR-08-1032